$1,318.00
This Market Spotlight report covers the pancreatic cancer market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, patent information, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
This Market Spotlight report covers the pancreatic cancer market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, patent information, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Key Takeaways
CONTENTS
6 OVERVIEW
7 KEY TAKEAWAYS
8 DISEASE BACKGROUND
8 Subtypes
10 TREATMENT
10 Surgery
10 Ablation or embolization
11 Radiation therapy
11 Chemotherapy
11 Targeted therapy
12 Immunotherapy
12 Drugs used specifically for the treatment of PNETs
13 EPIDEMIOLOGY
16 MARKETED DRUGS
19 PIPELINE DRUGS
34 RECENT EVENTS AND ANALYST OPINION
34 Motixafortide for Pancreatic Cancer (January 24, 2020)
35 Lynparza for Pancreatic Cancer (December 17, 2019)
36 Pegilodecakin for Pancreatic Cancer (October 16, 2019)
37 Acelarin for Pancreatic Cancer (August 20, 2019)
38 Mavorixafor for Pancreatic Cancer (July 17, 2019)
39 Napabucasin for Pancreatic Cancer (July 1, 2019)
40 Abraxane for Pancreatic Cancer (June 2, 2019)
41 Lynparza for Pancreatic Cancer (June 2, 2019)
42 NanoKnife System for Pancreatic Cancer (May 13, 2019)
43 MVT-5873 for Pancreatic Cancer (May 8, 2019)
45 KEY UPCOMING EVENTS
46 KEY REGULATORY EVENTS
46 Lynparza Gets US OK For Pancreatic Cancer
47 PROBABILITY OF SUCCESS
48 LICENSING AND ASSET ACQUISITION DEALS
48 Cytocom Goes Public Via Merger With Cleveland BioLabs
48 Exact Goes All-In On Multi-Cancer Screening With $2.15Bn For Thrive; $410M For Base Genomics
48 TriSalus Thinks Its Drug/Device Strategy Can Optimize IO Regimens
49 Processa Licenses IP For Next-Generation Irinotecan From Aposense
49 Bristol Myers Squibb declines to exercise Agios Pharmaceuticals opt-in right for AG-270
49 DeMelle Licenses Pancreatic Cancer Candidate From Moffit
49 Taiho Acquires Asian Rights To Arcus IO Candidate
50 Tyme, Eagle Collaborate On Development Of Pancreatic Cancer Drug
50 Astellas Taps Pandion In Pancreas Immunomodulator Deal
51 REVENUE OPPORTUNITY
53 CLINICAL TRIAL LANDSCAPE
54 Sponsors by status
55 Sponsors by phase
56 Recent events
57 BIBLIOGRAPHY
57 Prescription information
59 APPENDIX
LIST OF FIGURES
15 Figure 1: Trends in incident cases of pancreatic cancer, 2019–28
19 Figure 2: Overview of pipeline drugs for pancreatic cancer in the US
19 Figure 3: Pipeline drugs for pancreatic cancer, by company
20 Figure 4: Pipeline drugs for pancreatic cancer, by drug type
20 Figure 5: Pipeline drugs for pancreatic cancer, by classification
35 Figure 6: Motixafortide for Pancreatic Cancer (January 24, 2020): Phase Ib/II – w/Atezolizumab
37 Figure 7: Pegilodecakin for Pancreatic Cancer (October 16, 2019): Phase III – SEQUOIA (w/FOLFOX)
42 Figure 8: Lynparza for Pancreatic Cancer (June 2, 2019): Phase III – POLO
45 Figure 9: Key upcoming events in pancreatic cancer
47 Figure 10: Probability of success in the pancreatic cancer pipeline
53 Figure 11: Clinical trials in pancreatic cancer
53 Figure 12: Top 10 drugs for clinical trials in pancreatic cancer
54 Figure 13: Top 10 companies for clinical trials in pancreatic cancer
54 Figure 14: Trial locations in pancreatic cancer
55 Figure 15: Pancreatic cancer trials status
56 Figure 16: Pancreatic cancer trials sponsors, by phase
LIST OF TABLES
14 Table 1: Incident cases of pancreatic cancer, 2019–28
17 Table 2: Marketed drugs for pancreatic cancer
21 Table 3: Pipeline drugs for pancreatic cancer in the US
34 Table 4: Motixafortide for Pancreatic Cancer (January 24, 2020)
35 Table 5: Lynparza for Pancreatic Cancer (December 17, 2019)
36 Table 6: Pegilodecakin for Pancreatic Cancer (October 16, 2019)
37 Table 7: Acelarin for Pancreatic Cancer (August 20, 2019)
38 Table 8: Mavorixafor for Pancreatic Cancer (July 17, 2019)
39 Table 9: Napabucasin for Pancreatic Cancer (July 1, 2019)
40 Table 10: Abraxane for Pancreatic Cancer (June 2, 2019)
41 Table 11: Lynparza for Pancreatic Cancer (June 2, 2019)
43 Table 12: NanoKnife System for Pancreatic Cancer (May 13, 2019)
44 Table 13: MVT-5873 for Pancreatic Cancer (May 8, 2019)
51 Table 14: Historical global sales, by drug ($m), 2015–19
52 Table 15: Forecasted global sales, by drug ($m), 2020–24
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!